On Thursday, November 21, more than 800 new staff members joined Amgen as the company’s acquisition of Otezla® (apremilast) closed. Otezla fits naturally into Amgen’s franchise of innovative biologics and biosimilar products, and the addition of Otezla will help Amgen reach even more patients around the world.
The incoming Otezla team helped position the medicine as an important pre-biologic treatment across its approved indications through a dedicated focus on patients. With their help, Amgen will continue to drive strong growth performance and explore potential new indications for Otezla, while ensuring patients around the world have continued access to the medicines they need.
The Otezla team has shown impressive performance since the treatment’s first approval in 2014 and Amgen’s integration staff has worked to ensure their efforts to get critical therapy to patients continue during the transition.
For more information, please see the press release.